Mood Pearson

Key Concepts and Terminology

  • Emotions:

    • Individual feeling responses to a wide variety of specific stimuli, objects, or events (HE, 2023).

    • Reactionary, intense, focused, and relatively short-lived.

    • Core examples include joy, surprise, fear, anger, and disgust.

    • Frequently precipitate observable physiologic responses, such as smiling, frowning, clenching fists, pacing, sweating, and increased heart rate.

    • Difficult to prevent nonverbal expressions of emotion even if verbal communication is suppressed.

  • Mood:

    • An enduring state of mind rather than a discrete reaction (HE, 2023; Sikhon & Gupta, 2023).

    • Typically longer-lasting, less focused on a specific event or object, and less intense than emotions.

    • May have a single trigger, multiple triggers, or no identifiable cause at all.

    • Shapes an individual's general expectations about the future.

    • Does not produce direct observable physiologic reactions; described exclusively by the individual.

    • Clinicians must never assume a patient's mood based solely on external observations.

  • Affect:

    • The automatic, immediate, and observable external expression of mood (HE, 2023).

    • Represents an unconscious reaction to an event or situation as either good or bad (occurring as fast as within a few microseconds).

    • Contrast with emotion, which involves a conscious reaction.

    • Evidenced through both verbal and nonverbal responses.

  • Mental Health:

    • A state of well-being in which an individual works productively, copes effectively with typical life changes, and realizes their full potential.

  • Mental Illness:

    • A condition affecting emotions, thinking, behavior, or a combination thereof.

    • Confirmed when an individual experiences serious and lengthy impairment in functional ability (American Psychiatric Association [APA], 2022).

  • Continuum of Mood (Figure 28.1):

    • Depicted as a spectrum ranging from Depression (abnormally lowered mood marked by sadness, emptiness, and irritability) to Mania (abnormally elevated mood impairing functioning).

    • Euthymia: The central, stable range of mood that is neither pathologically elevated nor depressed. Fluctuations in euthymia are situation-appropriate, typical of baseline patterns, and non-impairing.

  • Affect Characteristics (Voss & Doss, 2022):

    • Appropriateness / Congruence: Degree to which affect matches the internal emotional state and immediate situational context.

    • Range: Variety of feelings conveyed.

    • Broad/Full Affect: Normal ability to convey a wide spectrum of feelings.

    • Restricted Affect: Expressing a limited range of feelings (e.g., weeping when describing a spouse's illness, but exhibiting no joy when discussing the birth of a child).

    • Intensity: Degree of emotion displayed.

    • Moderate Intensity: Emotional expression is appropriate and proportionate to the situation.

    • Overactive Intensity: Emotional expression is extreme or disproportionate.

    • Blunted Intensity: Emotional expression is dulled or muted.

    • Flat Intensity: Complete absence of visible emotional cues.

    • Stability: Frequency and rapidity of affect fluctuations.

    • Stable Affect: Consistent expression without external provocation.

    • Labile Affect: Rapidly changing affect out of proportion to stimuli, indicative of pathology.

Etiology and Pathophysiology of Altered Mood

  • Neurologic & Limbic System Structures:

    • Primary origins of emotions, mood, and affect lie in the limbic system, specifically the hippocampus, hypothalamus, and amygdala.

    • Regulation is controlled by the medial prefrontal cortex (MPFC).

    • MPFC dysfunction leads to limbic overactivity.

    • Brain imaging shows decreased gray matter volume and lower metabolic activity in the MPFC of individuals with mood alterations (Lee et al., 2022; Lemke et al., 2022).

    • Proper neuronal, neurotransmitter, and glial cell function are required for normal mood regulation (Simic et al., 2021).

  • Neurotransmitter Hypotheses:

    • Serotonin (5-HT5\text{-HT}): Regulates aggression, mood, anxiety, impulsivity, appetite, sleep, and sex drive.

    • Norepinephrine (NE\text{NE}): Regulates attention, arousal, and behavior (Jiang et al., 2022).

    • Monoamine dysregulation alone is insufficient to fully explain mood disorder etiology (Lee et al., 2022a).

    • Glutamate: Main excitatory neurotransmitter, regulating cognition, motivation, and emotional behaviors. Patients with depression exhibit elevated glutamate levels (Fries et al., 2023; Tian et al., 2022).

    • **GABA ($\gamma-aminobutyric acid\text{-aminobutyric acid})**: Primary inhibitory neurotransmitter. Levels are decreased in patients with depression.\n - **Dopamine (DA\text{DA})**: Regulates the reward activation system. Depressed patients show increased presynaptic DA transporter levels, leading to excessive DA reuptake (Tian et al., 2022).\n - **Hypothalamic-Pituitary-Adrenal (\text{HPA}$) Axis**: Dysregulation contributes significantly to mood disorders.\n\n- **Biological Rhythms**:\n - **Circadian Rhythms**: 24\text{-hour} cycles of biochemical and hormonal fluctuations governed by the hypothalamus (Poiraz et al., 2021; Wuerz-Justice, 2022).\n - Disruption causes altered sleep-wake cycles, hormonal fluctuations, mood swings, insomnia, and suicidality in bipolar disorders.\n - **Seasonal Rhythms / Seasonal Affective Disorder (\text{SAD})**: Formally diagnosed as Major Depressive Disorder with seasonal pattern. Manifests during specific times of year (typically winter) with decreased energy, hypersomnia, increased appetite, overeating, and weight gain (APA, 2022).\n\n- **Stress and Hormonal Factors**:\n - Chronic stress induces hormonal imbalances.\n - **Cortisol**: Primary stress hormone.\n - **Dehydroepiandrosterone (\text{DHEA})**: Steroid hormone improving physical well-being; acts antagonistically to cortisol.\n - Cortisol-to-DHEA ratio is correlated with Major Depressive Disorder (\text{MDD}) severity (Akhmed et al., 2023).\n\n- **Personality & Social Factors**:\n - High emotional instability (neuroticism), introversion, and low levels of conscientiousness/agreeableness predispose to negative affect and depression (Morera et al., 2021).\n - High perceived social support and large, diverse social networks serve protective roles against mood alterations (Akol et al., 2023; Jorley-Koch et al., 2022).\n\n- **Illness Status**:\n - Autoimmune conditions share immunologic links with mood disorders (Kotkoska & Sterzalevsky, 2022).\n - Chronic debilitating conditions (heart disease, diabetes, cancer) leading to loss of independence strongly correlate with depressive symptoms (Kernia-Widjaja et al., 2022; Yang & Darcy, 2022).\n\n# Clinical Manifestations and Classifications of Mood Disorders\n\n- **Anxious Distress Specifier**:\n - Included in DSM-5-TR for depressive and bipolar disorders (APA, 2022).\n - Core symptoms: restlessness, impaired concentration due to worry, fear of impending doom, fear of losing control.\n - *Safety Alert*: Patients with anxious distress are harder to treat and at significantly elevated risk for suicide.\n\n- **Major Depressive Disorder (\text{MDD} / Unipolar Depression)**:\n - Diagnostic criteria: Depressed mood or anhedonia (loss of interest/pleasure) present most of the day for at least 2\text{ weeks} consecutively (APA, 2022).\n - Must be accompanied by at least 4 of the following core symptoms:\n - Sleep disturbances (insomnia or hypersomnia).\n - Significant weight change (\ge 5\% gain or loss) or persistent appetite changes.\n - Fatigue or loss of energy.\n - Feelings of worthlessness or excessive/inappropriate guilt.\n - Psychomotor agitation or psychomotor retardation.\n - Diminished concentration or indecisiveness.\n\n- **Persistent Depressive Disorder (Dysthymia)**:\n - Depressed mood present for most of the day, more days than not, for at least 2\text{ years} (APA, 2022).\n - Symptoms are similar to MDD but less severe.\n\n- **Adjustment Disorder with Depressed Mood**:\n - Maladaptive reaction to an identifiable psychosocial stressor occurring within 3\text{ months} of stressor onset.\n - Persists no longer than 6\text{ months} after the termination of the stressor (APA, 2022).\n - Features depressive symptoms with prominent anxiety.\n\n- **Bipolar Disorders**:\n - **Bipolar I Disorder**: Characterized by at least 1manicepisodeandatleastmanic episode and at least1 major depressive episode.\n - *Mania*: Abnormal, persistent, elevated, expansive, or irritable mood lasting at least 1\text{ week} (or requiring hospitalization), causing severe functional impairment.\n - **Bipolar II Disorder**: Characterized by at least 1hypomanicepisodeandatleasthypomanic episode and at least1 major depressive episode.\n - *Hypomania*: Elevated mood lasting at least 4\text{ consecutive days}, causing noticeable functional changes but not requiring hospitalization.\n - **Diagnostic Specifiers**:\n - *With Mixed Features*: Depressive symptoms during manic/hypomanic episodes, or vice versa.\n - *With Rapid Cycling*: \ge 4moodepisodeswithinamood episodes within a12\text{-month}period,separatedbyatleastperiod, separated by at least2\text{ months} of remission or alternating polarity. Higher risk in women (Ato et al., 2019; Gaughan et al., 2019).\n\n- **Peripartum Mood Disorders**:\n - **Postpartum Blues**: Mild, self-limiting mood swings, tearfulness, anxiety, and sleep disruption. Onset within 2\text{--}3\text{ days}postpartum;lastsuptopostpartum; lasts up to2\text{ weeks} (CDC, 2023a).\n - **Peripartum Depression**: Moderate to severe depression arising during pregnancy or up to 1\text{ year}postpartum.Uptopostpartum. Up to50\% of cases begin antepartum.\n - **Postpartum Psychosis**: Occurs in 1\text{ in }500toto1\text{ in }1000 deliveries (APA, 2022). Emergency condition featuring command hallucinations (e.g., directing harm to infant) or delusions (e.g., believing baby is possessed).\n\n- **Common Manifestations & Complications**:\n - **Maladaptive Coping**: Avoidance, escape, rumination, denial, helplessness, isolation, self-pity, self-blame, excessive dependency, and aggression (Alton, 2023; Marcalongo-Pereira et al., 2022).\n - **Altered Cognition**: Indecisiveness, memory decay, poor problem-solving. Psychotic symptoms (delusions, paranoia, hallucinations) represent medical emergencies (MacIntyre et al., 2022).\n - **Somatization**: Expression of psychological distress via bodily complaints (headache, stomachache, nausea, fatigue, dizziness). Present in 50\% of primary care depression/anxiety patients (Mah et al., 2020); associated with alexithymia (Farhamandi et al., 2022).\n - **Suicide**: Extreme negative coping mechanism. Primary predictor is a past history of suicidal threats or attempts. Additional risk factors: adverse childhood experiences, male gender (higher completion rates), living alone, lethal method access, and persistent hopelessness (APA, 2022; CDC, 2021).\n\n# Epidemiology and Population Diversity\n\n- **Prevalence Statistics**:\n - Mood disorders affect approximately 11\% of adults (NAMI, 2024a).\n - Approximately 20\% of high school students experience suicidal ideation (NAMI, 2024b).\n - Over 21\text{ million}USadultshavehadatleastonemajordepressiveepisode(US adults have had at least one major depressive episode (14.7\%ofadultsof adults18+;;20.1\%ofadolescentsagedof adolescents aged12\text{--}17) (NIMH, 2023a).\n - Adolescent females aged 12\text{--}17havethehighestrateofmajordepressiveepisodesathave the highest rate of major depressive episodes at29.2\% (CDC, 2021).\n - Bipolar disorder prevalence is nearly equal between males (2.9\%)andfemales() and females (2.8\%).\n - Pandemic impact: Global anxiety and depression rose 25\%inthefirstyearofCOVID−19(WHO,2022a).Inin the first year of COVID-19 (WHO, 2022a). In2023,,32.3\%ofUSadultsreportedanxiety/depressionsymptoms,spikingtoof US adults reported anxiety/depression symptoms, spiking to52.8\% in households experiencing unemployment (Panchal et al., 2023).\n\n- **Sociocultural and Diversity Considerations**:\n - Older adult depression rates range between 10\%andand13\%, with older females at significantly higher risk (Chang & Mui, 2023).\n - Adolescent females experiencing discrimination or sociocultural disparities are 2\text{ to }3 times more likely to develop depression (Gomez-Baia et al., 2022; Wilson & Duvernay, 2022).\n - Black and Hispanic populations frequently seek support from family and faith communities first due to fear of involuntary commitment and medical distrust (Goetz et al., 2023; Morgan et al., 2023).\n - LGBTQIA+ population (18\text{ million}USindividuals):Recognizedhealthdisparitypopulation.LGBTQIA+adolescentsareUS individuals): Recognized health disparity population. LGBTQIA+ adolescents are3timesmorelikelytoreportpastsuicideattemptsandtimes more likely to report past suicide attempts and5 times more likely to make an attempt (Goldbach et al., 2021; Hughes et al., 2022).\n - Up to 66.5\% of transgender adolescents experience depression; gender-affirming care significantly reduces depression and suicidality (Endocrine Society, 2020; Tordoff et al., 2022).\n - Perinatal depression affects 17\% of US births among birthing parents identifying as LGBTQIA+ (Lapingar et al., 2023; Marceland et al., 2021).\n\n- **Genetic Factors**:\n - First-degree relatives of MDD patients have a 2\text{- to }4\text{-fold}increasedrisk;heritabilityisapproximatelyincreased risk; heritability is approximately40\% (APA, 2022; Tian et al., 2022).\n - Bipolar disorder carries a 10\text{-fold} risk increase among individuals with an affected relative.\n\n# Diagnostic Screening, Assessment, and Physical Workup\n\n- **Prevention and Screening Standards**:\n - Primary prevention: Nutrition (reduce sugar, saturated fat, refined foods; increase fruits, vegetables, legumes, fish, whole grains, omega-3 fatty acids, folic acid, vitamin D, selenium, calcium) (Ekinci & Sanlier, 2023; Ortega et al., 2022), regular exercise, sleep hygiene, smoking cessation (Wu et al., 2023), stress management, family CBT (Samer et al., 2023).\n - USPSTF recommendations: Screen all adults (including pregnant and postpartum individuals) and adolescents aged 12\text{--}18 for depression (USPSTF, 2022, 2023).\n - Common screening tool: Patient Health Questionnaire (PHQ-9), available in over 30 languages (APA, 2020; Vireo-Zagara et al., 2023).\n\n- **Nursing Assessment Procedures**:\n - Establish a therapeutic relationship based on mutual trust, using open-ended questions and brief, clear statements.\n - Behavioral observations: Hygiene, grooming, speech patterns (pressured, monotone), psychomotor agitation/retardation, dietary and fluid intake.\n - Patient history: Prior psychiatric diagnoses, family mental health history, sleep quality, substance use, chronic illness, coping mechanisms, financial status, and cultural beliefs.\n\n- **Physical Examination & Diagnostic Lab Workup**:\n - Vital signs, baseline weight, and Body Mass Index (\text{BMI}).\n - Thyroid function tests and endocrine hormone panels to rule out medical conditions mimicking depression or hypomania.\n - Electrolyte panels, urinalysis, and urine toxicology screen to evaluate substance abuse.\n - Liver function tests (LFTs) due to hepatic metabolism of psychotropic medications.\n - Pregnancy testing in females of childbearing age due to teratogenic potential of psychotropics (Chand & Arif, 2023).\n\n# Collaborative Interventions and Pharmacotherapy\n\n- **Suicide Prevention & Inpatient Safety**:\n - Risk increases when severe depression begins to improve (energy returns before mood elevates). Peak risk times during hospitalization occur during the first week of admission and at discharge (Chammas et al., 2022).\n - Continuous 1\text{-to-}1staffobservationforactivesuicidalintent(familymemberscannotreplacestaff;staff observation for active suicidal intent (family members cannot replace staff;15\text{-minute} checks are unsafe for high-risk patients).\n - Environment safety: Remove sharp items, razors, glass, mirrors, matches, belts, and straps. Inspect visitor items (prohibit outside food).\n - When suicidal ideation is expressed, confidentiality boundaries no longer apply.\n\n- **Pharmacotherapy for Depressive Disorders**:\n - Mechanisms: Selective Serotonin Reuptake Inhibitors (\text{SSRIs}),Serotonin−NorepinephrineReuptakeInhibitors(), Serotonin-Norepinephrine Reuptake Inhibitors (\text{SNRIs}),TricyclicAntidepressants(), Tricyclic Antidepressants (\text{TCAs}),andMonoamineOxidaseInhibitors(), and Monoamine Oxidase Inhibitors (\text{MAOIs})blockreuptakeorenzymaticdegradationof) block reuptake or enzymatic degradation of5\text{-HT}andand\text{NE}.\n - **Serotonin Syndrome**: Emergency caused by combining serotonergic agents (Strahan et al., 2023).\n - Symptoms: Altered mental status, neuromuscular abnormalities (tremor, hyperreflexia), autonomic instability (hypertension, tachypnea, tachycardia, diaphoresis), GI distress.\n - Action: Discontinue offending medications immediately and provide supportive care.\n - Patient Education: Full therapeutic onset requires several weeks; suicide risk elevates as energy increases; do not stop abruptly; avoid alcohol and OTC drugs; manage caloric intake/exercise to prevent weight gain.\n\n- **Pharmacotherapy for Bipolar Disorders**:\n - **Mood Stabilizers**: Lithium carbonate (\text{Lithobid}),atypicalantipsychotics(aripiprazole[), atypical antipsychotics (aripiprazole [\text{Abilify}],olanzapine[], olanzapine [\text{Zyprexa}]),andanticonvulsants(carbamazepine[]), and anticonvulsants (carbamazepine [\text{Tegretol}],valproicacid[], valproic acid [\text{Depakote}]).\n - *Safety Alert*: Prescribing antidepressant monotherapy to a bipolar patient in a depressive phase can precipitate a rapid switch into mania! Mood stabilizers must always be prescribed concurrently.\n - Monitoring: Blood drug levels, blood glucose, electrolytes, orthostatic hypotension, extrapyramidal symptoms (\text{EPS}),andneurolepticmalignantsyndrome(), and neuroleptic malignant syndrome (\text{NMS}).\n\n- **Nonpharmacologic & Interventional Therapies**:\n - **Cognitive Behavioral Therapy (\text{CBT})**: Reframes automatic negative thoughts into rational cognitive structures; incorporates cognitive modification and mindfulness training.\n - **Electroconvulsive Therapy (\text{ECT})**:\n - Induces brief controlled seizures; administered 2\text{--}3timesweeklyfortimes weekly for3\text{--}4weeks(totalweeks (total6\text{--}12 treatments). Twice-weekly administration is preferred (Salik & Marwaha, 2022).\n - Response rate exceeds 80\%((>60\%responsewithinresponse within3\text{ weeks}). Effective for treatment-resistant depression, severe suicidality, psychomotor retardation, and psychotic depression.\n - Requires general anesthesia, muscle relaxants, EEG/ECG, and pulse oximetry monitoring.\n - Adverse effects: Postictal confusion, transient short-term anterograde amnesia, rare permanent retrograde amnesia. Written informed consent is mandatory.\n - **Transcranial Magnetic Stimulation (\text{rTMS})**:\n - Electromagnetic coil targets left prefrontal cortex (depression) or right prefrontal cortex (mania). Onset within 1\text{--}2\text{ weeks}; fewer cognitive side effects than ECT (Sigrist et al., 2022).\n - **Complementary Approaches**:\n - Aerobic exercise: Moderate intensity 3\text{ times/week}foratleastfor at least9\text{ weeks} (Contreras-Osorio et al., 2022).\n - *St. John's Wort Safety Alert*: Unproven efficacy; severe risk of Serotonin Syndrome if combined with SSRIs/TCAs; reduces effectiveness of birth control, antiseizure, and HIV medications (NCCIH, 2023).\n\n- **Assertiveness Training & Boundary Management**:\n - **Assertive Behavior**: Expressing wishes and opinions clearly without violating others' rights.\n - **Aggressive Behavior**: Forcing desires on others using intimidation or discrediting tactics.\n - **Passive Behavior**: Avoiding conflict at all costs, leading to suppressed feelings, resentment, and passive-aggressive outbursts.\n - **Professional Boundaries**: Maintain short-term focus of nurse-patient relationship; decline personal contact requests to prevent maladaptive patient dependence.\n\n# Lifespan Considerations\n\n- **Children and Adolescents**:\n - Mood lability is common due to prefrontal cortex immaturity, puberty hormones, and developmental role adjustments (Kahnen, 2023; Silvers, 2022).\n - Depression prevalence: 4.4\%inchildrenagedin children aged3\text{--}17((2.7\text{ million})(CDC,2023b);) (CDC, 2023b);20\%inadolescentsagedin adolescents aged12\text{--}17 (NIMH, 2023).\n - **Fluoxetine (\text{Prozac})**: The only FDA-approved antidepressant for pediatric depression.\n - *FDA Black Box Warning (2004)*: Warns of heightened suicidal thoughts/behaviors in youth. Subsequent research revealed that reduced treatment initiation following the warning led to an actual increase in adolescent suicide attempts (Liu et al., 2020; Strahan et al., 2023).\n\n- **Pregnant Patients**:\n - Antepartum depression occurs in 12\%\text{--}20\% of pregnant women (Beck et al., 2022; Lou et al., 2022).\n - Pharmacotherapy risks: SSRIs (except paroxetine [\text{Paxil}])carrylowmajorbirthdefectrisks,butslightrisksforpersistentpulmonaryhypertensionofthenewborn(]) carry low major birth defect risks, but slight risks for persistent pulmonary hypertension of the newborn (\text{PPHN}) and neonatal withdrawal (Dysane et al., 2023; Gruszinski-Cinsak et al., 2023). MAOIs are contraindicated.\n\n- **Older Adults**:\n - Depression is NOT a normal component of aging; affects 10\%\text{--}13\% of older adults (NIH, 2021a).\n - Differentiate depression from dementia/grief; rule out physical causes.\n - Pharmacotherapy rule: Start low, go slow, treat to remission. SSRIs are first-line. Implement fall precautions for orthostatic hypotension.\n - *Safety Alert*: Atypical antipsychotics carry an FDA Black Box Warning for increased mortality secondary to pneumonia when administered to older adults with dementia-related psychosis.\n\n# Detailed Case Studies and Clinical Judgment Scenarios\n\n- **Case Study Part 1: Jason (Initial Presentation)**:\n - *Profile*: 22-year-old college student. Missed classes, failed to submit paper, isolated in apartment for days.\n - *Symptoms*: Anorexia, insomnia, severe guilt, lack of motivation, hunched posture, downcast eyes, tearfulness. Excellent prior semester, active in clubs, planned track team and student senate.\n - *Clinical Questions & Priorities*:\n - Priority issue: Assess immediate suicide risk and physical safety.\n - Affect description: Restricted, blunted to sad, non-congruent with past goals.\n - Physical health priorities: Sleep restoration, dietary/fluid intake. Lifestyle changes alone are insufficient if underlying clinical depression exists.\n - Additional data needed: Duration of symptoms, prior psychiatric history, family history, substance use, medical workup.\n - Family contact considerations: Mandated confidentiality unless active imminent suicide risk is present.\n - Sociocultural stressors: First time away from home, academic pressures, lack of local close support network.\n\n- **Case Study Part 2: Jason (1-Month Follow-Up)**:\n - *Medication*: Diagnosed with MDD; prescribed extended-release venlafaxine (\text{Effexor XR}).\n - *Behavioral Shift*: Mood described as "fabulous"; sleeping 2\text{ hours/night};heightenedsexualdesire;writingbookon"secrettomeaningoflife"forPulitzerPrize;runningforstudentsenate,trackteam,tutoring,drinking; heightened sexual desire; writing book on "secret to meaning of life" for Pulitzer Prize; running for student senate, track team, tutoring, drinking2\text{--}3\text{ nights/week};plans; plans5 accelerated summer courses. Speech is loud, rapid, and pressured; restless; states "A person as special as I am needs to be cloned, not killed."\n - *Clinical Assessment*:\n - Diagnosis shift: Antidepressant monotherapy (\text{Effexor XR}) unmasked/precipitated a manic episode (Bipolar I Disorder switch).\n - Affect: Elevated, euphoric, grandiose, overactive intensity, highly labile.\n - Priority safety considerations: Impulsivity, high-risk behaviors (alcohol abuse), exhaustion, potential rapid crash into severe suicidality.\n - Health teaching: Immediate discontinuation/tapering of antidepressant, initiation of mood stabilizer, safety and alcohol risks.\n\n- **Case Study Part 3: Jason (Inpatient Psychiatric Unit)**:\n - *Diagnosis & Treatment*: Admitted to Short-Term Acute Psychiatric Unit; diagnosed with Bipolar I Disorder; started on aripiprazole (\text{Abilify}))20\,mg daily.\n - *Current Status*: Restless, muscle twitches in hands (akathisia and mild dystonia). Speech normal, eating/sleeping improved. Expresses shame and severe stigma ("I can't face anyone... I'm crazy... What's the point?").\n - *Clinical Evaluation*:\n - Urgent reporting: Dystonic twitches and motor restlessness (\text{EPS} / akathisia) to physician for dose reduction or anticholinergic treatment (e.g., benztropine).\n - Immediate nursing assessment: Assess for emergent suicidal ideation ("What's the point?").\n - Priority nursing diagnosis: Risk for Suicide related to acute feelings of hopelessness, shame, and societal stigma.\n - Reason antidepressant was omitted: Antidepressants trigger manic relapse in Bipolar I without mood stabilizer co-administration.\n\n- **Case Study: Gerald Haynes (72-Year-Old Widower)**:\n - *Profile*: 72-year-old male brought by daughter due to 20\text{ lb}weightlossoverweight loss over2\text{ months}.Wifedied. Wife died3\text{ months}$$ ago.

    • Manifestations: Stopped church attendance, isolated from family, kitchen groceries unconsumed. States "I'm just not hungry anymore." Flat to sad affect, depressed mood. Physical labs negative/normal.

    • Clinical Evaluation:

    • Additional assessment questions: Assess suicidal ideation, sleep disturbances, cognitive decline, daily functional capacity, and mourning process vs. MDD.

    • Response to daughter: Re-educate that depression and profound severe functional decline are NOT normal parts of aging.

    • Priority care interventions: Establish suicide safety protocol, nutritional restoration/meal support planning, and initiate grief counseling / psychiatric evaluation for SSRI therapy.